athenahealth, Inc. | August 03, 2022
athenahealth, a leading provider of network-enabled software and services for medical groups and healthcare organizations nationwide, and health technology pioneer, DrFirst, today announced they are partnering to help improve medication adherence and patient outcomes. athenahealth’s large user base will now be able to send patient medication notifications powered by DrFirst’s RxInform to reduce prescription abandonment and help patients adhere to their recommended medication therapies.
Patients abandon 20% to 30% of new prescriptions, whether due to high out-of-pocket costs, concerns about side effects, procrastination, or other factors. This lack of medication adherence can lead to increased total cost of patient care and undesirable health outcomes, such as disease progression, hospitalization, or even death.
Now, the athenahealth electronic health record system that helps providers maximize clinical productivity and focus on delivering high-quality care to patients connects with RxInform, which automatically triggers a secure message to a patient’s mobile device when a clinician sends a prescription order to a pharmacy. From the message, patients may receive cost savings opportunities as available for a prescribed therapy and can view detailed information regarding their prescriptions, with a focus on behavioral and educational issues that have been proven to reduce prescription abandonment. The experience is seamless for the prescriber and helps them ensure the best outcomes for their patients.
“We are always looking for innovative ways to drive better results for our customers and their patients – especially as the industry shifts more toward value-based care. Every provider wants to minimize prescription abandonment rates because non-adherence to medication regimens negatively affects desired clinical outcomes. By adding RxInform to the latest release of athenaOne, we are immediately giving all our providers an automated function within their established prescribing workflows to support better patient outcomes.”
Paul Brient, chief product officer for athenahealth
Since 2017, RxInform has received more than three million patient ratings, with 92% overall positive scores. These results indicate that patients welcome these messages, presenting new opportunities for providers to nurture patient relationships and build loyalty outside of the exam room.
“Primary care providers and specialists who care for high-risk patients need tools to help people take their medications as prescribed,” said G. Cameron Deemer, president of DrFirst. “We’re pleased to partner with athenahealth to give its network of approximately 145,000 providers access to the RxInform platform so they can help patients overcome the common hurdles that lead them to abandon their medications at the pharmacy.”
About athenahealth, Inc.
athenahealth creates innovative healthcare technology that connects clinicians, patients, payers, and partners in differentiated ways. Our electronic health records, revenue cycle management, and patient engagement tools allow anytime, anywhere access, driving better financial outcomes for our customers and enabling our provider customers to deliver better quality care. In everything we do, we’re inspired by our vision to create a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all.
Since 2000, DrFirst has pioneered healthcare technology solutions and consulting services that securely connect people at touchpoints of care to improve patient outcomes. We create unconventional solutions that solve care collaboration, medication management, price transparency, and adherence challenges faced in healthcare. We unite the Healthiverse—the interconnected healthcare universe—by providing our clients with real-time access to the information they need, exactly when and how they need it, so patients get the best care possible. DrFirst solutions are used by nearly 325,000 healthcare professionals, including 220,000 prescribers, 70,000 pharmacies, 290 HIS/EHRs, and 1,500 hospitals in the U.S. and Canada.
Nanomix Corporation and BIOASIA PTE LTD. | August 24, 2022
Nanomix Corporation a leader in the development of mobile, affordable, point-of-care diagnostics, announced that it has entered into a distribution agreement with BIOASIA PTE LTD a medical diagnostics distributor located in Singapore. Bioasia will market and distribute the Nanōmix eLab® system in Singapore and Brunei, including the Nanōmix S1 Panel assay and future new test products for the eLab system.
“We are pleased to introduce and give access to much needed, new diagnostics to our hospitals and customers. Sepsis and critical infections are a challenge in Singapore in the same way they are around the world. Our partnership with Nanomix will help us bring a unique option to our customers and the healthcare system in Singapore.”
Henry Lim, Managing Director of Bioasia
Thomas Schlumpberger, Chief Executive Officer of Nanomix, stated, “Nanomix is at the cusp of commercialization and continues to show early successes in executing upon our commercialization strategy. We are excited to see increased interest in our products especially in Asia, beginning in Singapore, which represents a significant and untapped growth opportunity for Nanomix.”
John Hardesky, Chief Commercial Officer of Nanomix, stated, “Singapore has been ranked as one of the most efficient healthcare systems in the world for many years. The Nanōmix eLab® analyzer runs the S1 Panel assay rapidly, diagnosing critical infections including sepsis in 12 minutes which will undoubtedly lead to breakthroughs in earlier sepsis patient diagnosis.”
Sepsis is a recognized global health crisis. Early identification and treatment are a need and a challenge for healthcare professionals around the globe. For many reasons, sepsis can be difficult to identify and is frequently under-diagnosed in the earliest stages. It affects as many as 50 million people every year, leading to approximately 11 million deaths annually.
The Nanōmix eLab® system is a mobile, hand-held immunoassay and chemistry diagnostic system designed for the needs of rapid point-of-care testing. The Nanōmix eLab® system offers a variety of benefits, including results in minutes, lower cost, and portability, while providing accurate, quantitative results comparable in quality to those provided by central lab testing. Furthermore, the S1 Panel Cartridge was developed as an aid in rapidly diagnosing critical infections including sepsis. The panel provides quantitative test results for procalcitonin (PCT), C-reactive protein (CRP) and lactate (LAC) from a single venous whole blood or plasma sample type. The assay runs on the eLab® Analyzer with results available in approximately 12 minutes from sample to answer, versus the current diagnostic solutions which can take hours to provide a test result. The S1 Panel assay has received the CE marking in Europe and has UK Medicines and Healthcare products Regulatory Agency (MHRA) registration.
About BIOASIA PTE LTD
Bioasia was established in 2005 focusing on medical marketing and distribution of critical care products and monitoring equipment for patients requiring intensive care in intensive care settings. Our staff are professional biomedical engineers with knowledge of ISO13485. We work with medical professionals in hospital settings to ensure in-hospital equipment are at optimal working conditions for effective patient monitoring and results. Bioasia has represented various medical device companies in Singapore and Brunei markets since 2005. Bioasia is GDPMDS certified.
About Nanomix Corporation
Nanomix is developing mobile point-of-care diagnostics with its Nanōmix eLab® System platform and assays that provide rapid, accurate, quantitative information for use in settings where time is critical to clinical decision-making and improved patient care. The company’s products are designed to broadly impact healthcare delivery by bringing diagnostics to the point of initial patient interaction, whether in the hospital or in pre-hospital, remote or alternate-care settings, thereby enabling faster clinical decision-making and potentially treatment-in-place. Nanomix’s first assays address the need for faster diagnosis of critical infections including sepsis. The company is developing a pipeline of other tests designed to improve patient outcomes by making high-quality diagnostic information available within minutes.
Health Catalyst | September 08, 2022
Health Catalyst, Inc. a leading provider of data and analytics technology and services to healthcare organizations announced three new leadership assignments in support of its strategic focus areas moving forward. These strategic focus areas center around strengthening and deepening existing client relationships to enable greater success in realizing massive, measurable, data-informed improvement while continuing to add new client relationships.
This strategic focus includes the appointment of the company's current Chief Revenue Officer, Kevin Freeman, as Chief Growth Officer, and current Chief Brand and Communications Officer, Tarah Neujahr Bryan, as Chief Marketing Officer, effective September 7, 2022. In these roles, Kevin and Tarah will be responsible for the strategic growth functions at Health Catalyst, with a primary focus on expanding existing client relationships, and Kevin and Tarah will each report directly to Chief Executive Officer Dan Burton.
Kevin Freeman came to Health Catalyst in 2020 as part of the Vitalware acquisition, bringing 20+ years of healthcare IT growth leadership experience including publicly traded, private equity, and venture-capital-backed companies. He has a successful track record of building results-driven teams, strengthening client partnerships, and driving business development growth. Kevin has a Bachelor of Arts in Sociology from the University of Texas at Arlington.
Tarah Neujahr Bryan joined Health Catalyst in 2013 and has served as Editorial Director, Senior Vice President of Marketing, and Chief Brand and Communications Officer. She brings a breadth of marketing and communications experience to her current role. Prior to joining Health Catalyst, Tarah served as the Marketing Communications Director and the Foundation Executive Director at a community hospital, managed at an advertising agency, was the Editor and Operations Manager at an archaeology firm, and provided triage assistance and patient admissions at a Level-II Trauma Center. She has a Master of Arts in Journalism and Mass Communications from the University of Nebraska and a Bachelor of Arts from Montana State University-Billings.
Health Catalyst has also named Dave Ross, current Associate Chief Technology Officer, as Chief Technology Officer, also effective September 7, 2022. He will play a critical technology leadership role in building and enabling a world-class data and analytics infrastructure to support clients' efforts towards massive improvement in critical use-case areas such as tech-enabled outsourcing, financial empowerment, population health, and clinical improvement.
Dave Ross joined Health Catalyst in 2021 as part of the Twistle acquisition, and was previously the Chief Technology Officer and Co-Founder of Twistle, leading all product development and engineering activities for over ten years prior to Twistle being acquired by Health Catalyst. Before starting Twistle, Dave was the Director of Information Systems at Albany Medical Center in New York. He has built and led software development initiatives across healthcare and educational technology sectors and is passionate about finding the perfect intersection between engineering excellence and delivering business value. Dave holds a Bachelor of Science in Information Systems from SUNY Empire State College.
"This is a pivotal time for Health Catalyst as we work toward enabling the positive transformation of care for every patient served by our healthcare clients. I am grateful for each of these three world-class leaders moving into key positions, providing them with an increased opportunity to deliver on our long-term growth and vision to sustain our critical mission of being a catalyst, in deep partnership with our clients, to enable massive, measurable, data-informed healthcare improvement."
Chief Executive Officer Dan Burton
Related to the new growth leadership assignments, effective September 30, 2022, Patrick Nelli will transition from his role as President to that of Senior Advisor, where he will primarily focus on enabling a smooth transition of his prior responsibilities as President to Kevin Freeman, Chief Growth Officer, and to Dan Burton, Chief Executive Officer. Patrick joined Health Catalyst in 2013 and has played various roles contributing to the company's success, including as Chief Financial Officer from 2017 to January 2021, and as President from January 2021 to the present. Also, effective September 30, 2022, Bryan Hinton will complete his tenure at Health Catalyst. Bryan has contributed to Health Catalyst's growth and success in a number of roles since he joined the company in 2012, including most recently in the role of Chief Technology Officer.
Dan Burton shared, "I want to extend my heartfelt gratitude to Patrick and to Bryan for their many years of service and dedication to our mission, and for their incredible expertise and leadership in various roles over the years. They have deeply contributed to our company's mission, growth, and success. We are truly grateful to these outstanding colleagues, and we wish them continued success in their future endeavors."
About Health Catalyst
Health Catalyst is a leading provider of data and analytics technology and services to healthcare organizations committed to being the catalyst for massive, measurable, data-informed healthcare improvement. Its clients leverage the cloud-based data platform—powered by data from more than 100 million patient records and encompassing trillions of facts—as well as its analytics software and professional services expertise to make data-informed decisions and realize measurable clinical, financial, and operational improvements. Health Catalyst envisions a future in which all healthcare decisions are data informed.